- Trials with a EudraCT protocol (3,110)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (12)
3,110 result(s) found for: Lung Disease.
Displaying page 11 of 156.
EudraCT Number: 2010-023892-24 | Sponsor Protocol Number: ML25514 | Start Date*: 2011-01-26 | ||||||||||||||||
Sponsor Name:ROCHE | ||||||||||||||||||
Full Title: Phase II, open-label study of erlotinib (Tarceva) treatment In patients with locally advanced or metastatic non-small-cell lung cancer who present activating mutations in the tyrosine kinase domain... | ||||||||||||||||||
Medical condition: Stage IIIB, IV non-small-cell lung cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-012983-14 | Sponsor Protocol Number: DMS32212R | Start Date*: 2009-10-21 | |||||||||||
Sponsor Name:BioNumerik Pharmaceuticals, Inc. | |||||||||||||
Full Title: Randomized, multicenter, double-blind, phase 3 trial of Tavocept versus Placebo in patients with newly diagnosed or relapsed advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with... | |||||||||||||
Medical condition: Newly diagnosed or relapsed advanced (Stage IIIB/IV) primary adenocarcinoma of the lung | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001743-12 | Sponsor Protocol Number: INCB24360-208 | Start Date*: 2018-07-04 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Maligna... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Phase 1 (Dose Escalation): Advanced or metastatic solid tumors. Phase 2 (Dose Expansion): Advanced or metastatic non–small cell lung cancer (NSCLC), unresectable or metastatic melanoma (MEL) and r... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003331-30 | Sponsor Protocol Number: GO28915 | Start Date*: 2014-03-03 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON−SMALL CELL LUNG CAN... | |||||||||||||
Medical condition: NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SE (Completed) FI (Completed) IT (Completed) DE (Completed) PT (Completed) HU (Completed) NL (Completed) ES (Completed) PL (Completed) GR (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004592-11 | Sponsor Protocol Number: IGN101/2-02 | Start Date*: 2005-02-16 | |||||||||||
Sponsor Name:IGENEON | |||||||||||||
Full Title: Vaccination with IGN101 in patients with non-small-cell-lung-cancer (NSCLC) | |||||||||||||
Medical condition: Non-small-cell-lung-cancer stages IB, II A/B, III A | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016806-18 | Sponsor Protocol Number: TAX-ERB2 | Start Date*: 2010-12-09 | |||||||||||
Sponsor Name:Klinik Löwenstein gGmbH | |||||||||||||
Full Title: Multizentrische, randomisierte Phase II-Studie zur Therapie des lokal fortgeschrittenen oder metastasierten NSCLC im Stadium IV UICC 7 mit zwei unterschiedlichen Regimen von Cisplatin / Carboplatin... | |||||||||||||
Medical condition: patients with advanced or metastatic NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001044-72 | Sponsor Protocol Number: XRP6976B/2506 | Start Date*: 2005-01-17 | |||||||||||
Sponsor Name:AVENTIS PHARMA S.P.A. | |||||||||||||
Full Title: Randomized phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. | |||||||||||||
Medical condition: Non Small Cell Lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002811-98 | Sponsor Protocol Number: CALC-1 | Start Date*: 2005-07-01 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE | |||||||||||||
Full Title: Randomised phase II study of cetuximab in combination with gemcitabine or gemcitabine followed by cetuximab in patients with advanced non-small-cell lung cancer, not suitable for standard platin-ba... | |||||||||||||
Medical condition: Patients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003695-35 | Sponsor Protocol Number: D4200C00036 | Start Date*: 2007-01-24 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone i... | |||||||||||||
Medical condition: Locally-advanced or Metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) GR (Ongoing) PT (Completed) IT (Completed) BE (Completed) GB (Completed) ES (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003709-29 | Sponsor Protocol Number: ONC-2007-001 | Start Date*: 2008-06-17 | |||||||||||
Sponsor Name:ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: Prospective phase II trial evaluating efficacy of Trastuzumab therapy in HER2 FISH positive and/or HER2 mutation positive, pretreated, Non-Small Cell Lung Cancer patients (MO20509) | |||||||||||||
Medical condition: HER2 FISH POSITIVE AND/OR HER2 MUTATION POSITIVE, PRETREATED NON-SMALL CELL LUNG CANCER PATIENTS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003075-39 | Sponsor Protocol Number: TXTGEM OVER 70 | Start Date*: 2007-07-12 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: PROTOCOL OF TREATMENT WITH DOCETAXEL-GEMCITABINE IN OLD OR UNFIT PATIENTS WITH NSCLC STAGE IIIA, IIIB E IV. PHASE II TRIAL | |||||||||||||
Medical condition: Enrolment of old or unfit patient with age over 70, with Non Small Cell Lung Cancer, not operable stage IIIA, IIIB, IV | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003924-22 | Sponsor Protocol Number: ML39349 | Start Date*: 2017-05-03 | ||||||||||||||||
Sponsor Name:ROCHE SAS | ||||||||||||||||||
Full Title: AN OPEN-LABEL, MULTICENTER, SINGLE-ARM, PHASE II STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALECTINIB IN PATIENTS WITH ALK-REARRANGED NON−SMALL CELL LUNG CANCER AFTER DISEASE PROGRESSION ON PRIOR A... | ||||||||||||||||||
Medical condition: ALK-rearranged non-small cell lung cancer (NSCLC) after disease progression on prior ALK inhibitor therapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-019707-32 | Sponsor Protocol Number: 1199.82 | Start Date*: 2010-12-14 | ||||||||||||||||||||||||||
Sponsor Name:Boehringer Ingelheim | ||||||||||||||||||||||||||||
Full Title: LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology. | ||||||||||||||||||||||||||||
Medical condition: Advanced Non Small Cell Lung Cancer (recurrent or stage IIIB/IV) with squamous cell histology. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) NL (Prematurely Ended) PT (Prematurely Ended) DE (Completed) ES (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-021297-11 | Sponsor Protocol Number: I4T-MC-JVBA | Start Date*: 2011-03-07 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited, Indianapolis | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One P... | |||||||||||||
Medical condition: Stage IV Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) ES (Completed) IT (Completed) NO (Completed) AT (Completed) SE (Completed) GR (Completed) GB (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001849-15 | Sponsor Protocol Number: IFCT-1601 | Start Date*: 2016-08-10 | ||||||||||||||||
Sponsor Name:IFCT | ||||||||||||||||||
Full Title: A PHASE II PROSPECTIVE IMMUNE NEOADJUVANT THERAPY STUDY OF DURVALUMAB (MEDI4736) IN EARLY STAGE NON-SMALL CELL LUNG CANCER | ||||||||||||||||||
Medical condition: Stage IB (> 4 cm), II Non Small Cell Lung Cancer resectable | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001407-31 | Sponsor Protocol Number: D5160C00022 | Start Date*: 2015-10-28 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-... | ||||||||||||||||||
Medical condition: Stage IIIB or IV EGFRm NSCLC with T790M positive mutation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) BE (Completed) IT (Completed) AT (Completed) DK (Completed) ES (Completed) IE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006914-62 | Sponsor Protocol Number: BAY 43-9006 / 13266 | Start Date*: 2009-04-23 | |||||||||||||||||||||
Sponsor Name:Bayer HealthCare AG, 51368 Leverkusen, Germany | |||||||||||||||||||||||
Full Title: A Phase III, multi-center, placebo–controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2... | |||||||||||||||||||||||
Medical condition: Non-small cell lung carcinoma in patients with predominantly non-squamous cell carcinoma histology | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) BE (Completed) DE (Completed) AT (Completed) SE (Completed) ES (Completed) FR (Completed) BG (Completed) HU (Completed) GR (Completed) IT (Completed) GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-021120-96 | Sponsor Protocol Number: ML25279 | Start Date*: 2010-11-15 | ||||||||||||||||
Sponsor Name:Roche Products Limited | ||||||||||||||||||
Full Title: A study to assess the incidence of mutations in the tyrosine kinase domain of the epidermal growth factor receptor in UK patients with newly diagnosed locally advanced or metastatic non-small cell... | ||||||||||||||||||
Medical condition: Locally advanced or metastatic Non Small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004946-83 | Sponsor Protocol Number: BR.31 | Start Date*: 2015-02-19 | |||||||||||||||||||||
Sponsor Name:Clinipace GLobal Ltd. | |||||||||||||||||||||||
Full Title: A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer | |||||||||||||||||||||||
Medical condition: Completely resected non-small cell lung cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001750-34 | Sponsor Protocol Number: INCB39110-207 | Start Date*: 2017-12-11 | ||||||||||||||||
Sponsor Name:Incyte Corporation | ||||||||||||||||||
Full Title: An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non–Small Cell Lung Cancer | ||||||||||||||||||
Medical condition: Locally Advanced or Metastatic Non–Small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
